ClinicalTrials.gg
Status unknownNCT01714908RECELUpdated Feb 7, 2017

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

A Phase 2 interventional study of Erlotinib w Concurrent Radiotherapy and etoposide/cis-platin (EP) w Concurrent Radiotherapy in Non-small Cell Lung Cancer, sponsored by Jinming Yu. Status unknown at 19 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-02-07.

Sponsored by Jinming Yu · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2017), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 988 under way, 202 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
777th of 1,597
100 · median 100
Started
2012
with 29 others
Phase 2
653 of 1,885
274 open now
Registered
146th of 1,885
by date

Among the 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 777th largest by planned enrollment of the 1,597 interventional ones that give a count, is one of 30 that started in 2012, is one of 653 in phase 2, and was the 146th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

Erlotinib with concurrent radiotherapy has superior efficacy and comparable safety profile in unresectable stage III non-small cell lung cancer (NSCLC) patients with activating mutation of epidermal growth factor receptor (EGFR) in exon 19 or 21 versus etoposide plus cis-platin with concurrent radiotherapy.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • NSCLC
  • EGFR mutation
  • unresectable
  • erlotinib
  • concurrent radiotherapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • NSCLC confirmed by histopathology or cytology;
  • Stage IIA or IIIB NSCLC according to Tumor Node (TMN) staging of Lung Staging Standard version 7 2009, and be unresectable;
  • Has active mutation of EGFR in exon 19 or 21;
  • Has [according to (RECIST) 1.1, must have at least one evaluable lesion with the longest dimension >= 10mm; if the evaluable lesion is lymph node, the shortest dimension should be measured and >=15mm];
  • (ECOG) performance status (PS) 0-1;
  • expectancy life >= 12 weeks;

Exclusion criteria

Exclusion Criteria:

  • Had be treated by HER-targeting agents;
  • Had systemic anit-NSCLC treatments;
  • Had local radiotherapy for NSCLC;
  • Has upper gastrointestinal physiological disorders, or malabsorption syndrome, or intolerance of oral medication, or active peptic ulcer;
  • Diagnosed other malignant tumor besides NSCLC within 5 years prior the study treatment (except having simple surgical resection with 5-year disease free survival, cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder epithelial tumor);
  • Any evidence to indicate moderate or severe (COPD);
  • Known to platinum, etoposide, EGFR-Tyrosine Kinase Inhibitor (TKI) agents or relevant components in the formulation;
  • Uncontrolled eye inflammation or infection, or any potential circumstances lead to eye inflammation or infection;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Erlotinib w Concurrent Radiotherapy

    erlotinib 150mg oral daily up to 2 years concurrent radiotherapy total dose 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, and 5 fractions per week.

    Other: Erlotinib w Concurrent Radiotherapy

  • Active comparator
    etoposide/cis-platin (EP) w Concurrent Radiotherapy

    etoposide 50mg/m2 on D1-5 and D29-33 cis-platin 50mg/m2 on D1, D8, D29 and D36 concurrent radiotherapy total 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, 5 fractions per week.

    Other: etoposide/cis-platin (EP) w Concurrent Radiotherapy

Interventions

  • OtherErlotinib w Concurrent Radiotherapy
  • Otheretoposide/cis-platin (EP) w Concurrent Radiotherapy

    Etoposide / Cis-platin w Concurrent Radiotherapy

06

What researchers measure

Primary outcomes

  1. Progress Free Survival (PFS)

    The time frame from the randomization to the first confirmed disease progression or any cause to death (dependent on which comes first)

    Time frame: 5 years

07

Study locations

19 sites
  • Cancer Institute & Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Chinese PLA General Hospital
    Beijing, Beijing 100853, China
  • The General Hospital of the People's Liberation Army
    Beijing, Beijing 100853, China
  • Fujian Province Cancer Hospital
    Fuzhou, Fujian 350008, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Guizhou Cancer Hospital
    Guiyang, Guizhou 550004, China
  • Hebei Medical University Fourth Hospital
    Shijiazhuang, Hebei 050011, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430030, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Shandong Cancer Hospital and Institute
    Jinan, Shandong 250117, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
  • West China Hospital, West China School of Medicine, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • The First People's Hospital of Hangzhou
    Hangzhou, Zhejiang 310006, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2012 (actual). Primary completion is estimated for Aug 2018, 68 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 68 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2012
First posted
Oct 26, 2012
StartActual
Dec 14, 2012
Primary completionEst.
Aug 20, 2018
CompletionEst.
Oct 20, 2018
Last update
Feb 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01714908
Lead sponsor
Jinming Yu
Collaborators
Roche Pharma AG
Responsible party
Jinming Yu (Professor, Shandong Cancer Hospital and Institute) — Sponsor-investigator
First posted
Oct 26, 2012
Start date
Dec 14, 2012
Primary completion
Aug 20, 2018 (estimated)
Completion
Oct 20, 2018 (estimated)
Last update
Feb 7, 2017

Study contacts

Jinming Yu, PhD
study chair · Shandong Cancer Hospital and Institute
Shenglin Ma, PhD
principal investigator · The First People's Hospital of Hangzhou
Conghua Xie, PhD
principal investigator · Zhongnan Hospital
Ming Chen, PhD
principal investigator · Zhejiang Cancer Hospital
Gang Wu, PhD
principal investigator · Tongji Medical College, Huazhong University of Science and Technology, Wuhan Union Hospital
Jianhua Wang, PhD
principal investigator · Henan Cancer Hospital
Jiancheng Li, PhD
principal investigator · Fujian Province Cancer Hospital
Zhengfei Zhu, PhD
principal investigator · Fudan University
You Lu, PhD
principal investigator · West China Hospital, West China School of Medicine, Sichuan University
Lvhua Wang, PhD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Guangying Zhu, PhD
principal investigator · Peking University Cancer Hospital & Institute
Tingyi Xia, PhD
principal investigator · Chinese PLA General Hospital
Chun Han, PhD
principal investigator · Hebei Medical University Fourth Hospital
Guang Li, PhD
principal investigator · First Hospital of China Medical University
Zhiyong Yuan, PhD
principal investigator · Tianjin Medical University Cancer Institute and Hospital
Qin Lin, PhD
principal investigator · The First Affiliated Hospital of Xiamen University
Qibin Song, PhD
principal investigator · Renmin Hospital of Wuhan University
Yaping Xu, PhD
principal investigator · Zhejiang Cancer Hospital
Bing Lu, PhD
principal investigator · Cancer Hospital of Guizhou Province
Baolin Qu, PhD
principal investigator · Chinese PLA General Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion